Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 5/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30688670 | 0.90 | ENPP2 (0.65) | CYP4F2CYP4A11MAOBNR4A2ENPP2 | |
| SCHEMBL29138052 | 0.90 | ENPP2 (0.65) | CYP4F2CYP4A11MAOBNR4A2ENPP2 | |
| SCHEMBL12420271 | 0.90 | ENPP2 (0.54) | CYP4F2CYP4A11MAOBENPP2 | |
| SCHEMBL17236537 | 0.88 | APP (0.53) | CYP4F2CYP4A11MAOBBCHEENPP2 | |
| SCHEMBL3719564 | 0.87 | ENPP2 (0.47) | CYP4F2CYP4A11MAOBNR4A2BCHE | |
| SCHEMBL16687440 | 0.87 | ENPP2 (0.56) | CYP4F2CYP4A11MAOBENPP2 | |
| SCHEMBL16332337 | 0.86 | MEN1 (0.59) | CYP4F2CYP4A11MAOBNR4A2ENPP2 | |
| SCHEMBL29952469 | 0.85 | MAOB (0.62) | MAOBENPP2MAOARAB9A | |
| SCHEMBL23988 | 0.85 | NR4A2 (0.58) | MAOBNR4A2ENPP2MAOASMPD1 | |
| SCHEMBL16687442 | 0.85 | ENPP2 (0.64) | CYP4F2CYP4A11MAOBNR4A2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 680 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| EP-3995492-B1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2024-05-29 | — | — | EP | claimed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | claimed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | claimed |
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | claimed |
| US-20220264914-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-08-25 | — | — | US | claimed |
| WO-2022159439-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| EP-3995492-A1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2022-05-11 | — | — | EP | claimed |
| EP-3319941-B1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2021-12-29 | — | — | EP | claimed |
| EP-3319941-A1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx, LLC (US) | 2018-05-16 | — | — | EP | claimed |
| US-9914695-B2 | Two-step process for preparing 3-substituted phenylalkylamines | MALLINCKRODT LLC (US) | 2018-03-13 | — | — | US | claimed |
| WO-2017011231-A1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | MALLINCKRODT LLC (US) | 2017-01-19 | — | — | WO | claimed |
| US-20170008832-A1 | TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | MALLINCKRODT ENTERPRISES LLC | 2017-01-12 | — | — | US | claimed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008832-A1 | TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | PNMT, CYP1B1, UGT2B7 | CYP4F2 468/4885CYP4A11 167/4885MAOB 186/4885 |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | CYP4F2 4508/4885CYP4A11 2758/4885MAOB 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.